These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20203028)

  • 21. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug-resistant HIV.
    Laurence J
    AIDS Read; 2001 Aug; 11(8):384-5. PubMed ID: 11570260
    [No Abstract]   [Full Text] [Related]  

  • 23. Recent developments in HIV treatment, Part 2.
    Boyle BA
    AIDS Read; 2005 Jun; 15(6):277-9, 284. PubMed ID: 15962449
    [No Abstract]   [Full Text] [Related]  

  • 24. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
    Hill A; Sabin C
    AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 27. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2009; 17(2):57-67. PubMed ID: 19401608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy.
    Pomerantz RJ
    Am Fam Physician; 1999 May; 59(10):2855. PubMed ID: 10348077
    [No Abstract]   [Full Text] [Related]  

  • 30. Outbreaks of genital herpes: effects on plasma HIV type 1 viral loads in individuals receiving highly active antiretroviral therapy.
    Lee V; Foley E; Barton SE; Patel R
    J Infect Dis; 2004 Dec; 190(11):2057-8. PubMed ID: 15529276
    [No Abstract]   [Full Text] [Related]  

  • 31. XVI International AIDS Conference: Part 1.
    Boyle BA; Cohen CJ; Moyle GJ; Elion R; Sax PE; Frank I
    AIDS Read; 2006 Oct; 16(10):517-21. PubMed ID: 17096469
    [No Abstract]   [Full Text] [Related]  

  • 32. [CBO guidelines 'Antiretroviral therapy in the Netherlands'].
    Borleffs JC; Danner SA; Lange JM; van Everdingen JJ;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1585-9. PubMed ID: 11534375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
    Warszawski J; Tubiana R; Le Chenadec J; Blanche S; Teglas JP; Dollfus C; Faye A; Burgard M; Rouzioux C; Mandelbrot L;
    AIDS; 2008 Jan; 22(2):289-99. PubMed ID: 18097232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV treatment as prevention: [corrected] next steps.
    Duerr A
    Curr Opin HIV AIDS; 2012 Mar; 7(2):97-8. PubMed ID: 22241162
    [No Abstract]   [Full Text] [Related]  

  • 36. Rethinking STIs, revamping salvage, revisiting toxicity (or, the clouds of chronicity). 11th conference on retroviruses and opportunistic infections. February 8-11, 2004, San Francisco.
    Mascolini M
    IAPAC Mon; 2004 May; 10(5):154-76. PubMed ID: 15366102
    [No Abstract]   [Full Text] [Related]  

  • 37. CDC issues Q&A on ART and HIV transmission. 'Undetectable viral load does not mean...no virus'.
    AIDS Alert; 2010 Jul; 25(7):79-81. PubMed ID: 20812387
    [No Abstract]   [Full Text] [Related]  

  • 38. San Francisco benefits from decreased community viral load.
    AIDS Patient Care STDS; 2010 Apr; 24(4):265. PubMed ID: 20397900
    [No Abstract]   [Full Text] [Related]  

  • 39. "Test and treat": is it enough?
    Lange JM
    Clin Infect Dis; 2011 Mar; 52(6):801-2. PubMed ID: 21367735
    [No Abstract]   [Full Text] [Related]  

  • 40. A PrEP rally. Key updates on pre-exposure prophylaxis and HIV-specific antibodies were among the main attractions at the annual Conference on Retroviruses and Opportunistic Infections.
    Kresge KJ; McEnery R
    IAVI Rep; 2011; 15(2):11-5, 18. PubMed ID: 21608325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.